Acute Lymphoblastic Leukemia (ALL)Phase 2NCT02338050
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study testing Moxetumomab Pasudotox in people with Acute Lymphoblastic Leukemia (ALL), run by Center for International Blood and Marrow Transplant Research at 4 sites in United States.
Trial summary
This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting to patients with B-lineage Acute Lymphoblastic Leukemia (ALL) who are in a morphologic… Read more about this study
- Who is it for?
- Ages 6 months to 24 years
- Conditions the study is for
- Acute Lymphoblastic Leukemia (ALL)
- What is being tested?
- Moxetumomab Pasudotox
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 4 sitesUnited States
- Study dates
- May 2015to May 2020
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 24 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- ≥ 6 months and < 25 years of age
- Histologically confirmed diagnosis of B-lineage ALL. Verification of CD22 expression is not required
- Bone marrow in morphologic remission (any remission number) defined as < 5% blasts (M1 classification) performed in local institution lab
- CNS 1 (< 5/μL WBCs in CSF and cytospin negative for blasts)
- Evidence of bone marrow MRD defined as ≥ 0.01% by flow cytometry performed in the study central lab
- Candidate committed to HCT independent of participation in this study, with the following requirements:
Show all 21Show fewer
- Meets local transplant center eligibility requirements for HCT
- In the opinion of the HCT center will be ready to begin pre-transplant conditioning within 6 weeks of trial enrollment from a medical and psychosocial standpoint
- Has an available HCT donor or identified cord blood unit. Related and unrelated donors, and bone marrow, peripheral blood, or cord blood stem cell sources allowed
- Adequate organ function including the following:
- Hepatic function: Total bilirubin < 1.5 × upper limit of normal (ULN) (except in the case of subjects with known Gilbert's disease: < 5 × ULN) and transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) < 3 × ULN based on age- and institution specific laboratory-specific normal ranges
- Renal function: Age-adjusted normal serum creatinine is required. A 24-hour creatinine clearance value > 60 mL/min/1.73 m2 (updated Schwartz formula or nuclear GFR) must be obtained if serum creatinine is elevated.
- Hematologic function: Absolute neutrophil count (ANC) > 500/μL and platelet count > 25,000/μL without transfusion
- Oxygen saturation at rest or with exercise > 88% as measured by pulse oximeter or PaO2 > 55 mm Hg without need for supplemental oxygen at rest or with activity
- Serum albumin > 2 g/dL
- Performance status:
- Subjects ≥ 16 years of age: Karnofsky ≥ 60% (Appendix A)
- Subjects < 16 years of age: Lansky scale ≥ 60% (Appendix A)
- Subjects who are unable to walk because of paralysis, but who are upright in a wheel chair will be considered ambulatory for the purpose of calculating the performance score
- Patients > 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for patients < 18 years of age. Pediatric patients will be included in age appropriate discussion in order to obtain assent
- Sexually active female subjects of childbearing potential and male subjects and their sexual partners who are of childbearing potential must agree to use contraception
Who cannot join
- Active extramedullary disease at any site. (Note: Definitive therapy of known previous sites of extramedullary disease is allowed)
- Females who are breast-feeding or pregnant
- Subjects with known 11q23 MLL rearrangement are excluded.
- Prior therapy:
- Prior treatment with CAT-3888 (BL22), moxetumomab pasudotox (CAT-8015, HA22), any pseudomonas-exotoxin-containing compound, or any anti-CD22 directed therapy at any time in the past
- Prior allogeneic or autologous HCT or adoptive cellular therapies, including T-cell chimeric antigen receptor (CAR) therapy
Show all 18Show fewer
- Chemotherapy < 2 weeks prior to starting study drug with the following exception: There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such
- Monoclonal antibody therapy < 30 days from study enrollment
- Other investigational agents currently or within 30 days prior to study enrollment
- Subjects with an absolute contraindication to corticosteroid administration
- HIV infection (due to increased risk of severe infection and unknown interaction of moxetumomab pasudotox with antiretroviral drugs)
- Active hepatitis B or C infection as defined by seropositivity for hepatitis B (hepatitis B surface antigen [HbsAg]) or hepatitis C (hepatitis C antibody) and elevated liver transaminases (defined as above the ULN per the institution normal ranges)
- Second malignancy other than non-basal cell carcinoma of the skin or in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and subject is in remission
- Subject with clinical or laboratory evidence of active DIC
- Subject with prior history of thrombotic microangiopathy or HUS within 3 months prior to enrollment
- History of known congenital hypercoagulable condition
- Previous life-threatening anaphylactic reactions to prior monoclonal antibody-based immunotherapy or any component of the moxetumomab pasudotox formulation
- Subjects who will be or are currently being treated with high dose estrogen (high dose is defined as >0.625mg daily as conjugated estrogens or equivalent) within 7 days prior to study enrollment
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Children's Hospital Colorado
Aurora, Colorado, 80045
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Childrens Hospital of Los Angeles
Los Angeles, California, 90027
University of California San Francisco
San Francisco, California, 94143
About this study
Official title: A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting to patients with B-lineage Acute Lymphoblastic Leukemia (ALL) who are in a morphologic complete remission and have pre-transplant minimal residual disease (MRD) > 0.01% (detected by flow cytometry). The primary objective of this study is to determine if treatment with moxetumomab pasudotox in the MRD positive setting is able to lead to MRD negativity (< 0.01% by flow cytometry) or at least a 1-log10 reduction in MRD prior to allogeneic HCT.
Read the detailed description
This is a Phase 2 study designed to assess safety, feasibility and clinical activity of pre-HCT moxetumomab pasudotox for patients with ALL in morphologic CR but with MRD. It is hypothesized that subjects in a morphologic complete remission with proven minimal residual disease (MRD) after chemotherapy for ALL planned for allogeneic HCT who receive a course of moxetumomab pasudotox prior to the start of conditioning will show a marked reduction or elimination of detectable MRD after moxetumomab pasudotox treatment without adverse impact on the feasibility or safety of allogeneic HCT.
The primary objective of this study is to determine if treatment with moxetumomab pasudotox in the MRD positive setting is able to lead to MRD negativity (< 0.01% by flow cytometry) or at least a 1-log10 reduction in MRD prior to allogeneic HCT.
Secondary objectives to be studied include: toxicity profile (including safety and feasibility of administration in the pre-HCT setting and ability to proceed to transplant, incidence of capillary leak syndrome, hemolytic uremic syndrome and other post-HCT toxicities), comparison of quantitative MRD assessments, progression-free survival, overall survival, pharmacokinetic profiles, immunogenicity to moxetumomab pasudotox, transplant-related mortality, acute and chronic graft-versus-host disease (GVHD), and relapse.
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Being tested
- Moxetumomab Pasudotox
- Keywords
- ALL, Moxetumomab Pasudotox, Moxe, CAT-8015, HA22
- Medical subject headings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Moxetumomab PasudotoxBiological
Also called (CAT-8015, HA22)
| Study group | Role | What they receive |
|---|---|---|
| Moxetumomab Pasudotox | Experimental | Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox. Receives: Biological: Moxetumomab Pasudotox |
What is being measured
The primary outcome is the main question the study is designed to answer.
MRD negativity
The primary endpoint is the event of whether patients successfully achieved either MRD negativity (defined as <0.01%) or at least 1 log10 reduction in MRD levels using flow cytometry via central laboratory testing after moxetumomab treatment but prior to HCT relative to pre-moxetumomab MRD measurement (baseline). The proportion of patients who become MRD negative or who have at least a 1-log10 reduction from baseline will be summarized and 80% confidence intervals will provided. An exploratory analysis of the association between CD22 expression at eligibility and the response rate will also be conducted.
Measured: change in MRD levels between baseline and 3-10 days post last Moxe dose
Secondary outcomes (11)
MRD level and its log reduction from baseline
will be described quantitatively at each time point using median and range. Values that go below the lower limit of detection (<0.01%) will be set to the lower limit to obtain a conservative estimate of the log reduction. A test of whether the MRD levels are significantly reduced relative to baseline will be conducted using the Wilcoxon signed rank test. Agreement between quantitative MRD assessments using flow cytometry and molecular sequencing (immunosequencing) will be assessed using reliability coefficients and Bland-Altman plots, applied to the log transformed MRD levels. The correlation between CD22 expression at eligibility and log reduction in MRD from baseline will be described using Spearman's rank correlation.
Measured: baseline and 3-10 days post last Moxe dose
Overall Survival (OS)
is defined as the time from the start of treatment with moxetumomab pasudotox until death for the treated population. The OS will be censored if the patient did not die at the end of the study. For transplant population, the start time is from the date of transplant. Kaplan-Meier estimator will be used for the median or survival rate at a particular time.
Measured: from Moxe Dose 1 through date of death from any cause (assessed through 2 years post HCT or last Moxe dose)
Progression-free survival (PFS)
is defined as the time from the start of treatment with moxetumomab pasudotox until the documentation of disease progression or death due to any cause, whichever occurs first, for the treated population. PFS will be censored if the patient did not relapse by the last visit. For transplant population, the start time is from the date of transplant. Kaplan-Meier estimator will be used for the median or survival rate at a particular time.
Measured: from Moxe Dose 1 through date of progression or death from any cause (assessed through 2 years post HCT or last Moxe dose)
Proportion of patients proceeding to transplant
will be described, along with a breakdown of the reasons for not proceeding to transplant and their frequencies.
Measured: from Moxe Dose 1 through Day 0 of transplant
Relapse
Relapse will be defined by the presence of > 5% bone marrow blasts by morphology on an aspirate sample, or by evidence of peripheral blasts or extramedullary disease. The proportion of relapse will be summarized for both the treated population (from start of treatment) and transplant population (from date of transplant), using the cumulative incidence estimator with death in the absence of relapse as the competing event.
Measured: from Moxe Dose 1 through date of relapse (assessed through 2 years post HCT or last Moxe dose)
Transplant-related mortality (TRM)
An event for this endpoint is death without evidence of disease progression or recurrence. TRM will be summarized using cumulative incidence for transplant population.
Measured: from Day 0 of transplant through date of death without evidence of disease progression or recurrence (assessed through 2 years post HCT)
Acute GVHD
The events are the incidences of grades II-IV and grades III-IV acute GVHD from day of transplant. The first day of acute GVHD onset at a certain grade will be used to calculate a cumulative incidence curve for that acute GVHD grade. Death is considered as a competing risk. Transplant population will be used.
Measured: from Day 0 of transplant through first onset date of acute GVHD grades II-IV and grades III-IV (assessed through 2 years post HCT)
Chronic GVHD
The cumulative incidence of chronic GVHD starting at the day of transplant will be summarized, treating death as a competing risk. Transplant population will be used.
Measured: from Day 0 of transplant through first onset date of chronic GVHD (assessed through 2 years post HCT)
Clinical Laboratory Values
The values and abnormalities for relevant laboratory tests will be summarized by descriptive statistics (e.g., number of subjects, mean, standard deviation, median, minimum, maximum, proportions, etc.) at each time point and also for change from baseline value. Baseline will be defined as the last non-missing value prior to treatment with moxetumomab pasudotox.
Measured: from baseline through 3-10 days post last Moxe dose
Pre-transplant toxicities: Pre-transplant adverse events
Pre-transplant adverse events will be collected until 30 days after the last dose of study drug or until transplant and will be tabulated by severity and relationship to the study drug. Post-transplant adverse events will be analyzed separately as described in the next section.
Capillary Leak Syndrome, hemolytic uremic syndrome, ocular toxicities and cytokine release syndrome/infusional reactions, as well as death which is possibly, probably or definitely related to moxetumomab pasudotox are Adverse Events of Interest and will be further analyzed by examining their correlation with other clinical variables.
Measured: from Moxe Dose 1 through 30 days after the last dose of study drug or until start of conditioning regimen
Post-Transplant Toxicities: Unexpected SAEs
Unexpected SAEs will be tabulated by severity and relationship to study drug. The cumulative incidence of thrombotic microangiopathy (TMA), and hepatic veno-occlusive disease (VOD) will be described in transplanted patients, treating death as a competing risk. Transplanted population will be used for these analyses.
Measured: start of conditioning regimen and continuing for 60 days from Day 0 of transplant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2015 (estimated)
- Study startMay 2015
- Primary completionMay 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Lymphoblastic Leukemia (ALL)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Sponsor type
- Research network
- Collaborators
- National Marrow Donor Program, Pediatric Blood and Marrow Transplant Consortium, MedImmune LLC, St. Baldrick's Foundation
- Responsible party
- Sponsor
- Investigators
- Alan S Wayne, MD, Study chair, Children's Hospital Los AngelesNirali N Shah, MD, Study chair, National Institutes of Health (NIH)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02338050
- Sponsor's protocol ID
- 12-MOXE
- Status last verified
- Sep 2015
- First submitted
- 6 Jan 2015
- Last updated
- 16 Sep 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Shah NN, Schneiderman J, Kuruvilla D, Bhojwani D, Fry TJ, Martin PL, Schultz KR, Silverman LB, Whitlock JA, Wood B, Vainshtein I, Adams A, Confer D, Pulsipher MA, Chaudhury S, Wayne AS. Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 Jan;68(1):e28574. doi: 10.1002/pbc.28574. Epub 2020 Sep 22. No abstract available.
PubMed 32959985
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
- ClinicalTrials.gov ID
- NCT02338050
- Acronym / sponsor ID
- 12-MOXE
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Keywords
- ALL, Moxetumomab Pasudotox, Moxe, CAT-8015, HA22
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Center for International Blood and Marrow Transplant ResearchResearch network
- Collaborators
- National Marrow Donor Program, Pediatric Blood and Marrow Transplant Consortium, MedImmune LLC, St. Baldrick's Foundation
- Study start
- May 2015
- Primary completion
- May 2020 (estimated)
- First posted
- 14 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting to patients with B-lineage Acute Lymphoblastic Leukemia (ALL) who are in a morphologic complete remission and have pre-transplant minimal residual disease (MRD) > 0.01% (detected by flow cytometry). The primary objective of this study is to determine if treatment with moxetumomab pasudotox in the MRD positive setting is able to lead to MRD negativity (< 0.01% by flow cytometry) or at least a 1-log10 reduction in MRD prior to allogeneic HCT.
Detailed description
This is a Phase 2 study designed to assess safety, feasibility and clinical activity of pre-HCT moxetumomab pasudotox for patients with ALL in morphologic CR but with MRD. It is hypothesized that subjects in a morphologic complete remission with proven minimal residual disease (MRD) after chemotherapy for ALL planned for allogeneic HCT who receive a course of moxetumomab pasudotox prior to the start of conditioning will show a marked reduction or elimination of detectable MRD after moxetumomab pasudotox treatment without adverse impact on the feasibility or safety of allogeneic HCT.
The primary objective of this study is to determine if treatment with moxetumomab pasudotox in the MRD positive setting is able to lead to MRD negativity (< 0.01% by flow cytometry) or at least a 1-log10 reduction in MRD prior to allogeneic HCT.
Secondary objectives to be studied include: toxicity profile (including safety and feasibility of administration in the pre-HCT setting and ability to proceed to transplant, incidence of capillary leak syndrome, hemolytic uremic syndrome and other post-HCT toxicities), comparison of quantitative MRD assessments, progression-free survival, overall survival, pharmacokinetic profiles, immunogenicity to moxetumomab pasudotox, transplant-related mortality, acute and chronic graft-versus-host disease (GVHD), and relapse.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Moxetumomab Pasudotox | Experimental | Biological: Moxetumomab PasudotoxMoxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox. |
Who may qualify
- Ages
- 6 months to 24 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (21 listed)
- ≥ 6 months and < 25 years of age
- Histologically confirmed diagnosis of B-lineage ALL. Verification of CD22 expression is not required
- Bone marrow in morphologic remission (any remission number) defined as < 5% blasts (M1 classification) performed in local institution lab
- CNS 1 (< 5/μL WBCs in CSF and cytospin negative for blasts)
- Evidence of bone marrow MRD defined as ≥ 0.01% by flow cytometry performed in the study central lab
Key exclusion criteria (18 listed)
- Active extramedullary disease at any site. (Note: Definitive therapy of known previous sites of extramedullary disease is allowed)
- Females who are breast-feeding or pregnant
- Subjects with known 11q23 MLL rearrangement are excluded.
- Prior therapy:
- Subjects with an absolute contraindication to corticosteroid administration
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Moxetumomab PasudotoxAlso: (CAT-8015, HA22) | Biological | Moxetumomab Pasudotox |
Primary outcome
MRD negativity
Time frame: change in MRD levels between baseline and 3-10 days post last Moxe dose
The primary endpoint is the event of whether patients successfully achieved either MRD negativity (defined as <0.01%) or at least 1 log10 reduction in MRD levels using flow cytometry via central laboratory testing after moxetumomab treatment but prior to HCT relative to pre-moxetumomab MRD measurement (baseline). The proportion of patients who become MRD negative or who have at least a 1-log10 reduction from baseline will be summarized and 80% confidence intervals will provided. An exploratory analysis of the association between CD22 expression at eligibility and the response rate will also be conducted.
11 secondary outcomes
MRD level and its log reduction from baseline
Time frame: baseline and 3-10 days post last Moxe dose
Overall Survival (OS)
Time frame: from Moxe Dose 1 through date of death from any cause (assessed through 2 years post HCT or last Moxe dose)
Progression-free survival (PFS)
Time frame: from Moxe Dose 1 through date of progression or death from any cause (assessed through 2 years post HCT or last Moxe dose)
Proportion of patients proceeding to transplant
Time frame: from Moxe Dose 1 through Day 0 of transplant
Relapse
Time frame: from Moxe Dose 1 through date of relapse (assessed through 2 years post HCT or last Moxe dose)
Transplant-related mortality (TRM)
Time frame: from Day 0 of transplant through date of death without evidence of disease progression or recurrence (assessed through 2 years post HCT)
Acute GVHD
Time frame: from Day 0 of transplant through first onset date of acute GVHD grades II-IV and grades III-IV (assessed through 2 years post HCT)
Chronic GVHD
Time frame: from Day 0 of transplant through first onset date of chronic GVHD (assessed through 2 years post HCT)
Clinical Laboratory Values
Time frame: from baseline through 3-10 days post last Moxe dose
Pre-transplant toxicities: Pre-transplant adverse events
Time frame: from Moxe Dose 1 through 30 days after the last dose of study drug or until start of conditioning regimen
Post-Transplant Toxicities: Unexpected SAEs
Time frame: start of conditioning regimen and continuing for 60 days from Day 0 of transplant
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2015.
- Derived from this study: PubMed 32959985Shah NN, Schneiderman J, Kuruvilla D, Bhojwani D, Fry TJ, Martin PL, Schultz KR, Silverman LB, Whitlock JA, Wood B, Vainshtein I, Adams A, Confer D, Pulsipher MA, Chaudhury S, Wayne AS. Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 Jan;68(1):e28574. doi: 10.1002/pbc.28574. Epub 2020 Sep 22. No abstract available.
Related trials for Acute Lymphoblastic Leukemia (ALL)
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alan S Wayne, MD study chair
Children's Hospital Los Angeles
Nirali N Shah, MD study chair
National Institutes of Health (NIH)
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Moxetumomab Pasudotox in people with Acute Lymphoblastic Leukemia (ALL), run by Center for International Blood and Marrow Transplant Research at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 16 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MRD negativity (time frame: change in MRD levels between baseline and 3-10 days post last Moxe dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02338050, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2015.